GL
Monte Rosa Therapeutics, Inc.
GLUE · NASDAQ
$12.99 -6.14% (-$0.85)
1M -8.52%
Market Cap $1.17B
P/E Ratio -
Div. Yield -
ROE 43.31%
Bulios Fair Price
$11.57
10.9% downside
Current Price
$12.99
Undervalued Fair Value Overvalued
According to Bulios Fair Price, GLUE is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
39 /100
Fair P/S 40.88x
P/B 2.41x
P/E N/A
Growth
0 /100
Declining Book val. growth 4.95%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak Gross margin 92.94%
Net margin 560.85%
Op. margin 633.04%
Quality
0 /100
Poor ROIC 28.09%
ROE 43.31%
ROA 23.15%
Debt
100 /100
Low Debt/Equity 0.08x
Current ratio 9.52x
Int. coverage N/A
Stability
33 /100
Unstable Beta 1.50x
EPS volatility 41.99%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GLUE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Markus Warmuth
Employees
173
Headquarters
Boston
Upcoming events
05 NOV
Earnings
Upcoming earnings report